AsiaNet-Pakistan Premier Editorial Content and Press Release Distribution Service
NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tungray Technologies Inc (NASDAQ: TRSG) resulting from allegations that Tungray Technologies may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Tungray […]
Read More »ROSEN, LEADING TRIAL ATTORNEYS, Encourages Crocs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CROX
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Crocs, Inc. (NASDAQ: CROX) between November 3, 2022 and October 28, 2024, inclusive (the “Class Period”), of the important March 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Crocs common stock during […]
Read More »ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Newmont Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NEM
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Newmont Corporation (NYSE: NEM) between February 22, 2024 and October 23, 2024, inclusive (the “Class Period”). A class action lawsuit has already been […]
Read More »ROSEN, A LONGSTANDING LAW FIRM, Encourages Target Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – TGT
NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Target Corporation (NYSE: TGT) between August 26, 2022 and November 19, 2024, both dates inclusive (the “Class Period”). A class action lawsuit […]
Read More »Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- – Enrollment of Phase […]
Read More »Yandex develops and open-sources Perforator, an open-source tool that can save businesses billions of dollars a year on server infrastructure
Perforator Yandex introduces Perforator, a tool that can identify and evaluate code inefficiencies across a company’s entire code base. Perforator helps developers identify the most resource-intensive sections of code and provides detailed statistics for subsequent optimization. The solution can help businesses reduce CPU resource usage by 20% annually. By leveraging Perforator, companies can potentially save […]
Read More »ياندكس تطور وتفتح المصادر Perforator، أداة مفتوحة المصدر يمكنها توفير مليارات الدولارات للشركات سنويًا على البنية التحتية للخادم
Perforator تقدم Yandex أداة Perforator، وهي أداة يمكنها تحديد وتقييم أوجه القصور في التعليمات البرمجية عبر قاعدة التعليمات البرمجي الكاملة للشركة يساعد Perforator المطورين على تحديد أقسام التعليمات البرمجية الأكثر استهلاكًا للموارد ويوفر إحصائيات مفصلة للتحسين اللاحق. ال يمكن أن يساعد هذا الحل […]
Read More »